Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, C. P, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical And Research Reports 2022, 3: 100381. PMID: 36082279, PMCID: PMC9445394, DOI: 10.1016/j.jtocrr.2022.100381.Peer-Reviewed Original ResearchWhole transcriptome sequencingTranscriptome sequencingSplice siteMet stabilityDonor splice siteNext-generation sequencingTranscriptomic levelSplicing alterationsEnrichment analysisJunction pathwayPoint mutationsPotential therapeutic targetGenomic alterationsRNA expressionSequencingGene signaturePathwayMutational burdenGenomic profilingSynergistic increaseExpressionMost alterationsCheckpointTherapeutic targetSingle-sample gene